Celgene's last hurrah at ASH a defining moment for Bristol-Myers' buyout

Mark this year's American Society of Hematology meeting as one of the last times the biopharma community sees Celgene as an independent company.

The storied biotech is going out with a bang, however, with plans to release pivotal trial results for its leading cancer cell therapy lisocabtagene maraleucel, or liso-cel. Securing FDA approval of the drug by the end of 2020 is an essential step to its investors receiving $6 billion more from buyer Bristol-Myers Squibb.